Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing.

Ali Raza Khaki,Leonidas Nikolaos Diamantopoulos,Marita Zimmerman,Louis P. Garrison,Petros Grivas

Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing.

2020

Ali Raza Khaki
Leonidas Nikolaos Diamantopoulos
Marita Zimmerman
Louis P. Garrison
Petros Grivas

5031Background: Data from interim analysis of IMvigor130 trial showed that 1st line treatment of advanced urothelial cancer (aUC) with atezolizumab (Atezo) + platinum-based chemotherapy (PBC) signi...

Keywords:

urothelial cancer
Physical therapy
Atezolizumab
Oncology
Value-based pricing
first line
platinum chemotherapy
cost effectiveness
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations